Pushing back on drug resistance

摘要

Lung tumours may contain a mix of drug-resistant and drug-sensitive cells. Modified drug regimens could exploit this to delay the emergence of resistant tumours. Certain non-small-cell lung cancers commonly acquire drug resistance, most often through a mutation called T790M in the gene EGFR.